Cognition Clinical Trial
— EDXOfficial title:
A Crossover Study to Examine Exercise-Induced Rates of Fat Oxidation With and Without Ingestion of a Caffeine-Based Energy Drink
NCT number | NCT06308731 |
Other study ID # | 23-26 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 19, 2024 |
Est. completion date | July 1, 2024 |
Verified date | March 2024 |
Source | Lindenwood University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate acute changes in rates of fat oxidation during exercise with and without the ingestion of a caffeine-based energy drink.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | July 1, 2024 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Male or female participants between 18 - 50 years of age - Signed informed consent - Healthy defined as currently not being treated for an active cardiac, pulmonary, metabolic, immunological, neurological, respiratory, orthopedic, musculoskeletal, psychiatric, or reproductive disease or disorder. With the research team and principal investigator's discretion, some ongoing treatments will be permitted if a determination is made that the treatment will not increase the risk of study participation and the treatment will not confound with desired study outcomes - Physically active which is defined as performing aerobic or resistance-based physical exercise between 2 and 5 times per week - Moderate caffeine users (~300 mg/day) - Body mass index values will range from >24.0 to < 31.9 kg/m2. The average body mass index for the entire study cohort will be less than 31.99 kg/m2. As such, an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 31.99 kg/m2 - Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures Exclusion Criteria: - Body mass index > 31.9 kg/m2 - Positive medical history and/or is currently being treated for some form of heart or cardiovascular, neurological impairment, disease or condition, immune disorder or disease, thyroid disease, kidney disease, renal failure, regular dialysis, liver disease, or other diagnosed hepatic impairment - Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL) - Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year - History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). - Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) - Currently prescribed statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha-blockers, Vasodilators, etc.) or any other medication at the discretion of the principal investigator - Current smoker (>10 cigarettes per day) - Participants who are lactating, pregnant, or planning to become pregnant - History of alcohol or substance abuse in the 6 months prior to screening - Receipt or use of an investigational product in another research study within 60 days of beginning the study protocol - Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data - Extensive travel (>1 month) that will disrupt the original outline of the study protocol |
Country | Name | City | State |
---|---|---|---|
United States | Exercise and Performance Nutrition Laboratory | Saint Charles | Missouri |
Lead Sponsor | Collaborator |
---|---|
Lindenwood University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Impact of a caffeine-based energy drink ingestion on adverse events | Self-reported adverse events | 3 weeks | |
Other | Impact of a caffeine-based energy drink ingestion on heart rate | Heart rate (bpm) | 3 weeks | |
Other | Impact of a caffeine-based energy drink ingestion on blood pressure | Blood Pressure (mmHg) | 3 weeks | |
Primary | Impact of a caffeine-based energy drink ingestion on fat oxidation rates during exercise. | Fat oxidation rate (grams/min) during exercise | 150 minutes during exercise | |
Secondary | Impact of a caffeine-based energy drink ingestion on energy expenditure rates during exercise. | Energy expenditure (kcals/min) | 150 minutes during exercise | |
Secondary | Impact of a caffeine-based energy drink ingestion on carbohydrate oxidation during exercise | Carbohydrate oxidation rates (grams/min) | 150 minutes during exercise | |
Secondary | Impact of a caffeine-based energy drink ingestion on plasma glycerol concentration | Plasma glycerol concentration | 150 minutes after intervention ingestion | |
Secondary | Impact of a caffeine-based energy drink ingestion on plasma free fatty acid concentration | Plasma free fatty acid concentration | 150 minutes after intervention ingestion | |
Secondary | Impact of a caffeine-based energy drink ingestion on ratings of perceived exertion | Rating of Perceived Exertion (RPE) scale | 150 minutes after intervention ingestion | |
Secondary | Impact of a caffeine-based energy drink ingestion on exercise performance | Cycling time trial | 150 minutes after intervention ingestion | |
Secondary | Impact of a caffeine-based energy drink ingestion on reaction time | Simple/ choice reaction time | 150 minutes after intervention ingestion | |
Secondary | Impact of a caffeine-based energy drink ingestion on trail making test performance | Trail making test | 150 minutes after intervention ingestion | |
Secondary | Impact of a caffeine-based energy drink ingestion on Cognition | Serial 7 Cognitive processing test | 150 minutes after intervention ingestion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04540523 -
Home-Based Exergaming Intervention
|
N/A | |
Suspended |
NCT01212029 -
Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging
|
N/A | |
Enrolling by invitation |
NCT05273970 -
Electrochemical and Electrophysiological Study
|
N/A | |
Recruiting |
NCT05227352 -
Bio-Experiential Spaces for Mental Health in Healthworkers
|
N/A | |
Completed |
NCT02671149 -
The Effect of Small Changes in Hydration on Cognition
|
N/A | |
Completed |
NCT01333306 -
Enhancing Cognitive Training Using tDCS
|
Phase 1 | |
Recruiting |
NCT05542199 -
Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
|
N/A | |
Recruiting |
NCT06254638 -
Effectiveness of a Multicomponent Intervention to Promote Physical Activity Levels During the School Day (MOVESCHOOL)
|
N/A | |
Recruiting |
NCT06331286 -
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
|
N/A | |
Completed |
NCT05998096 -
A Randomized Study to Examine the Ability of a Caffeine-Based Energy Drink to Impact Energy Expenditure, Fat Oxidation, Reaction Time, and Other Perceptual Indicators
|
N/A | |
Withdrawn |
NCT03224559 -
Applying Neuromodulation to Accelerate Training Effects
|
||
Completed |
NCT03129048 -
Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults
|
N/A | |
Recruiting |
NCT05394363 -
Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
|
||
Suspended |
NCT05107947 -
Light in Frail Elderly - the Effect of a Dynamic Light for Sleep and Circadian Rhythm
|
N/A | |
Recruiting |
NCT05372172 -
Tennessee Alzheimer's Project
|
||
Recruiting |
NCT05132517 -
Magnesium and Cognition After Stroke
|
||
Recruiting |
NCT05992571 -
Oral Ketone Monoester Supplementation and Resting-state Brain Connectivity
|
N/A | |
Recruiting |
NCT06097182 -
Postbiotic Intervention for Acute Stress Management
|
N/A | |
Completed |
NCT01223404 -
Nicotinic Modulation of the Default Network
|
N/A | |
Completed |
NCT00687102 -
Cognition in the Study of Tamoxifen and Raloxifene
|
Phase 3 |